ASCO '13 Live Blog: Prepping for Monday Trading

CHICAGO ( TheStreet) -- We get to see how cancer drug stocks fare in Monday trading following a weekend of data presentations at the American Society of Clinical Oncology (ASCO) annual meeting.

Patrick Crutcher of Chimera Research Group and I are here for the next hour or so discussing the best and worst from the ASCO weekend to get ready for Monday's market open. Please join us and bring your questions and comments.

The anti-PD-1 drugs from Bristol-Myers Squibb ( BMY) and Merck ( MRK) are generating the biggest buzz at this year's ASCO for the dramatic benefit observed in early-stage studies of advanced melanoma patients. Expectations for Bristol-Myers' nivolumab were high going into the conference but Merck may have stolen the show Sunday with lambrolizumab data that look as good or better.

The weekend also brought incremental updates of the B-cell cancer drugs from Pharmacyclics ( PCYC) (ibrutinib), Gilead Sciences ( GILD) (idelalisib) and Infinity Pharmaceuticals ( INFI) (INF-145.)

There was so much more happening this weekend at the ASCO annual meeting, so let's discuss.

-- Reported by Adam Feuerstein in Chicago.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Jim Cramer's Investing Rule 12: Cash Is for Winners

Jim Cramer's Investing Rule 12: Cash Is for Winners

Video: Here's Where to Put Your Money Amid Trade War Fears

Video: Here's Where to Put Your Money Amid Trade War Fears

The Single Biggest Reason Trade War Fears Could Finally Topple the Stock Market

The Single Biggest Reason Trade War Fears Could Finally Topple the Stock Market

2 Best Oil Trades Ahead of Key OPEC Meeting

2 Best Oil Trades Ahead of Key OPEC Meeting

Activist-Targeted Rent-A-Center Sold to Vintage

Activist-Targeted Rent-A-Center Sold to Vintage